Merck Clocked $950M Sales In Q4 From COVID-19 Treatment, Issues FY22 Sales

Loading...
Loading...

Merck & Co Inc's MRK Q4 sales reached $13.52 billion, +24% Y/Y, beating the consensus of $13.16 billion. 

  • Excluding the foreign exchange impact, revenues were up 23%.
  • Pharmaceutical sales increased 23% to $12 billion, reflecting sales of molnupiravir and growth in oncology, vaccines, and hospital acute care products. 
  • COVID-19 treatment drug Molnupiravir sales were $952 million, primarily consisting of sales in the U.S., the U.K., and Japan.
  • Related: Merck's COVID-19 Pill works Against Omicron, Lab Studies Show.
  • Keytruda sales grew 15% to $4.6 billion. Vaccine sales rebounded, and Gardasil/ Gardasil 9 sales were up 53% to $1.5 billion, primarily driven by strong global demand, particularly in China.
  • Vaccine performance was negatively affected by lower sales of PNEUMOVAX 23 pneumococcal vaccine, which declined 14% to $292 million on lower demand in the U.S., reflecting prioritization of COVID-19 vaccines.
  • Adjusted EPS of $1.80 also surpassed the analysts' estimate of $1.53 and up from $0.98 posted a year ago.
  • 2022 Guidance: Merck expects FY22 sales of $56.1 billion - $57.6 billion, compared to the consensus of $56.64 billion.
  • It expects an adjusted EPS of $7.12 and $7.27 (consensus $7.29).
  • Price Action: MRK shares are down 0.33% at $81.74 during the premarket session on the last check Thursday.
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: BiotechEarningsNewsGuidanceHealth CareGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...